Unichem Labs bags USFDA nod for chronic angina drug Ranolazine Extended Release

Ranolazine Extended-Release Tablets, 500 mg, and 1000 mg are indicated for the treatment of chronic angina.

Published On 2023-03-17 07:45 GMT   |   Update On 2023-10-11 09:50 GMT
Advertisement

Mumbai: Unichem Laboratories Limited has announced that the company has received ANDA approval for its Ranolazine Extended-Release Tablets, 500 mg and 1000 mg from the United States Food and Drug Administration (USFDA).

The product is a generic version of Ranexa (ranolazine extended-release tablets) 500 mg and 1000 mg, of Gilead Sciences Inc.

Ranolazine Extended-Release Tablets, 500 mg, and 1000 mg are indicated for the treatment of chronic angina. Chronic angina is a prevalent manifestation of cardiovascular disease. It is most commonly due to insufficient oxygen supply from fixed epicardial lesions in the coronary arteries.

Advertisement

The product will be commercialized from Unichem’s Goa Plant.

Read also: Unichem Labs anticonvulsant drug Carbamazepine gets USFDA okay

Headquartered in Mumbai, Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. The company was founded in 1944 by Padmabhushan Late Mr. Amrut V Mody. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world. 

Read also: Unichem Labs bags USFDA nod for Extended Phenytoin Sodium Capsules



Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News